title: Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience.
abstract: BACKGROUND
  Esophageal small-cell carcinoma (SCC) is rare, highly malignant and the optimal treatment approach has not been defined.
  
  
  METHODS
  We report the largest single-institution retrospective review of patients with esophageal and gastroesophageal (GE) junction SCC.
  
  
  RESULTS
  Twenty-five patients were identified, with complete records available for 22. Eighty-two percent were male, 82% had pure SCC histology and 86% of tumors were in the lower esophagus or GE junction. On the basis of the Veterans' Administration Lung Study Group criteria, 14 patients (64%) presented with limited disease (LD). Median survival was 19.8 months (range, 1.5 months to 11.2+ years); for LD patients, 22.3 months (range, 6 months to 11.2+ years); for extensive disease (ED) patients, 8.5 months (range, 1.5 months to 2.2 years, P = 0.02). With a median follow-up of 38 months, six patients (27%) are alive, one with ED and five with LD. Two LD patients are alive and free of disease for >5 years. Four of the five LD patients who are long-term survivors received induction chemotherapy followed by chemoradiotherapy without surgery.
  
  
  CONCLUSIONS
  Our data indicate that patients with LD esophageal SCC treated with induction chemotherapy followed by consolidative chemoradiation can achieve long-term survival. The contribution of surgery remains unclear.
authors.affiliation: Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
authors.forename: G Y
authors.initials: GY
authors.lastname: Ku
authors.forename: B D
authors.initials: BD
authors.lastname: Minsky
authors.forename: V W
authors.initials: VW
authors.lastname: Rusch
authors.forename: M
authors.initials: M
authors.lastname: Bains
authors.forename: D P
authors.initials: DP
authors.lastname: Kelsen
authors.forename: D H
authors.initials: DH
authors.lastname: Ilson
mesh_terms: D000368:Aged; D018288:Carcinoma, Small Cell / Q000401:mortality* / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D004943:Esophagogastric Junction; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome